{"name":"Aspireo Pharmaceuticals Limited","slug":"aspireo-pharmaceuticals-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DG3173","genericName":"DG3173","slug":"dg3173","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DG3173","genericName":"DG3173","slug":"dg3173","phase":"phase_2","mechanism":"DG3173 is a small molecule that targets the [unknown molecular target] to exert its therapeutic effects.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOSVBINkNXVDYtd05ybFRQR2hObDgwR1FWQU96Uk1NNDlGcmJqWm1SOHRZQ0I3MktnUGlqeXkyRlg4TFpfMzBWb2VKUTd3YnJjUkVpWFY0eXNUZGZLY0NQbXh3bVV5NG82V1QyN0xpNEIxTVREZnNfTVJYdGNBY2tSRmlVelQyLUh1QjVlZEREQVFZR09TdkxoWA?oc=5","date":"2026-01-28","type":"trial","source":"Endpoints News","summary":"Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters - Endpoints News","headline":"Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxObk52UEk3LURQaUx4cHJGQkRLdGY0QjdSTGJ0ek9jME5Ia3ZsM1NFa0RJaFhFWDRfZmxvd2phc1dXNzloTXFRYnZpekhGSV8yWV9jUWNLejJ5Y2lPVWtsbzFfTkF2Ym5rWVJvdjF6U0lxSFlRdWJOdXFZUzh3eW01dG82Q0RGOWFiTmtUZm0wSGhDUGdHQUdhSklubGVtZkI0eG5HQ2hiVDRmR2czWFFhclBGUEhIbDJJcUtoME1B?oc=5","date":"2026-01-07","type":"regulatory","source":"Stock Titan","summary":"FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan","headline":"FDA backs trial of faster-acting aspirin powder for heart attacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOMEJZVzQ2MG0wX21XUDI1em5fOV83UkIyclVYcFlocnVZWEhIdjdmdnNjeTYzQlAzanNOWm91eXh2SE5OMGtaakc3eFAyajFGV09CVUZldDVyZ3BaZ1pScGNUOUk1dGIyRENsQXN2ZldPbVJKYWRhOGdsMnlWZDJ5Z043MHY2UGNJSE55elRWUGtjeE9hOW9TTU9CLTBQZElld3hz?oc=5","date":"2025-12-11","type":"earnings","source":"USA Today","summary":"Aspire Biopharma Provides Q3 2025 Business Update - USA Today","headline":"Aspire Biopharma Provides Q3 2025 Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBTVFJQdHlqTl9YYmpNNkxRZzdjRWRoeUpPX3JhQzlDaHRkUFNSMWdZaU9YQXk2M2c3UWppbmFuOFJzWE0zblEzX2cteDhDM09YTUdIck5qamI1cExjRGdRa2pGSy1SZ05ZREE?oc=5","date":"2025-12-02","type":"pipeline","source":"PharmaTimes","summary":"The young ones - PharmaTimes","headline":"The young ones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOdkU3cmhva0ZLaXVqVlFZTldzeXpYcWdrOEh1NVJpWkdrazVfRk11ajVRbEM0dWpJdE9TQ1Q5YmI4Vjlka1VJVC1DU1V0OVRIMlR5RGpWUzhLQzVVTjdsd3VQMzZENjMzalNYT1hCd1BVSXRma3ZadjlFX2RPak1rR3pHUzVDbVFzd0dWTnJmWQ?oc=5","date":"2025-11-26","type":"pipeline","source":"PMLiVE","summary":"The building of Aspire Pharma and values - PMLiVE","headline":"The building of Aspire Pharma and values","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE0zNGs5dGJDNXhZS3pWbDMxWHNId3hheTZSSjFjS3h6UW1qMWRuZ1lQaVdUMm9jdm5VY054c1Z3NEdUWDNBOFJxUE9UQVEwWXZiZks3YmJqUjc5T2cyaVFNQ2UzQjNxMTFfQUw4?oc=5","date":"2025-09-19","type":"pipeline","source":"The Pharma Letter","summary":"Aspire Pharma - The Pharma Letter","headline":"Aspire Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTjV1U2J5LXRwN3Zhd1pIcHVrOXZWRTVNY3lnQ293VlY0ZjNQOHpmenhFWGx1YWtrWXRjc2VtZTUxSDd2cE9ramtITXpIMXg2NTB2MkdqMUM4WGl5ekpnMWllUV80aTd5dUdjR3lrMGZZM1k4Zzh4Q3RLZnV5Y3NMOWlVYlBacjdickNsLU00SjJWRlVRellWRWNGU0t5enJ1czN6MnQ5QWpVVDZOVWduQjhCcVUwUmVmczd3NUtZVDhSZw?oc=5","date":"2025-07-31","type":"trial","source":"Ultragenyx","summary":"Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome - Ultragenyx","headline":"Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNeWROVnJsUURmUnZqSFFaN1lfR0ZONVVHUkVTY0ROYXQwWEVmR2dUcjVDNUpQWm5sdmdhbWVPV21KeEVMNF9pS0pSbjVsU2FUUnpaYlVuYzNIcXRKNXd0S0pJaDJzSGszUjJpZTAycWM1b3pEc3FqOUNQUk9kam9RTWtjRVpMTS11RFM0N1QyZEdvdWh3d1ZCelZjNmtvNUktcElDU2RiMNIBrAFBVV95cUxORVZOZE5fckh6UDlvQ3hCdU5Sb0RKNUNyZGFpWmNub19YMWlUdnZkRHZVX3IzeVhRdmVBVmJmWFV2dGItVFVZRDJUUGgzOHRXbnVERW9DbVFoYzJ4ZXBpQ3A0YzdRZG5hLUpxMl9HcEt4R2I3d21aV093OVM1NExGUFBfWTg1WkRLeHlVbGswclNCallURjNVc2tKRXYwcS1FZ1JCV0ZoT29oX1d4?oc=5","date":"2025-07-15","type":"pipeline","source":"Express Pharma","summary":"Aspire Impact and Aspire Circle launch ESG Framework for Pharma & Healthcare - Express Pharma","headline":"Aspire Impact and Aspire Circle launch ESG Framework for Pharma & Healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE01U2FKV0lGYUMxakMzYUJZeGNIak9MYi1rZkZsamdsMDFpY3FRVnZCaVdBUWZKclpXWWdlWlBfc2pxaW9nMURkcHVPU0N6aVBWS19vYWRCNERjY1N0a2VwUVlXSGkxTlA5ZkE?oc=5","date":"2025-06-03","type":"pipeline","source":"PharmaTimes","summary":"Leading lights - PharmaTimes","headline":"Leading lights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQU1JQMGpPZjRmSldFWUJxUUNocE05LXU4VV9PdVp5U2V3cDJVa1YtRXRIYjlhbWdHY3d5a0dCd1NUUnhOUGlnRGYzcWk5d3N2eEpzNzJya21WWFRvcHBjNG1ITk5OQjFxOHl0Y3l5TXV5dGhaUDlSaWtfQ09pSGlhdWFCMmJnUHFyRG1mVU5oSVdDQQ?oc=5","date":"2025-04-21","type":"pipeline","source":"Insightace Analytic","summary":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOcXdPalRQb2I3aFl0YjFodFh3MkhaOTFuTFVBS3g2aE5YZ3lKZHhYb21OU0VMY0tKOEtOMHYwNEtaTzJCdUtMVTljaWc3bDlackFFUXczYXltLTR1QzBJT0k0TzNvQU4zUXJycE1mS2kyT0dFb1FJbVZRZ0NIbzRqYzg2amV6VDV6MGs2eFNn?oc=5","date":"2025-02-20","type":"pipeline","source":"Yahoo Finance","summary":"Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - Yahoo Finance","headline":"Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOdVdCMHpuUVpMb0hYYVNxODFZZlBoNWZrT1pCQ0FPUFowVFNYZnFnenFnNlhSdEZhN1ZuZkVsbHhURW9xc3p0WUhPZjNaUHRFMWNVdmp0X2swc0FGMzhYaFpDcnU0cllFZElTUG10SjNkbGRIYndCVHFkNUZ3TmpVM0lhMlFrRGpzeGlKY05OZjhmUXRFN1A3SVlB?oc=5","date":"2021-09-24","type":"deal","source":"Business Wire","summary":"H.I.G. Capital Acquires Aspire Pharma - Business Wire","headline":"H.I.G. Capital Acquires Aspire Pharma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}